Creative Planning Purchases New Shares in Myovant Sciences Ltd (NYSE:MYOV)

Share on StockTwits

Creative Planning purchased a new stake in Myovant Sciences Ltd (NYSE:MYOV) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 11,818 shares of the company’s stock, valued at approximately $183,000.

A number of other large investors also recently added to or reduced their stakes in the stock. Barclays PLC boosted its holdings in shares of Myovant Sciences by 24.6% during the 3rd quarter. Barclays PLC now owns 11,317 shares of the company’s stock valued at $59,000 after buying an additional 2,234 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Myovant Sciences by 46.3% during the 3rd quarter. Tower Research Capital LLC TRC now owns 9,741 shares of the company’s stock valued at $51,000 after buying an additional 3,083 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Myovant Sciences by 133.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,518 shares of the company’s stock valued at $86,000 after buying an additional 3,154 shares in the last quarter. Northern Trust Corp bought a new stake in shares of Myovant Sciences during the 2nd quarter valued at $105,000. Finally, BlackRock Inc. boosted its holdings in shares of Myovant Sciences by 59.1% during the 2nd quarter. BlackRock Inc. now owns 44,637 shares of the company’s stock valued at $404,000 after buying an additional 16,580 shares in the last quarter. Institutional investors and hedge funds own 39.44% of the company’s stock.

MYOV opened at $11.71 on Friday. The stock has a 50-day moving average price of $13.77 and a 200-day moving average price of $9.93. The company has a debt-to-equity ratio of 5.88, a current ratio of 2.79 and a quick ratio of 2.79. The firm has a market cap of $1.05 billion, a PE ratio of -3.16 and a beta of 2.11. Myovant Sciences Ltd has a 1 year low of $4.14 and a 1 year high of $26.02.

Myovant Sciences (NYSE:MYOV) last posted its quarterly earnings results on Monday, February 10th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.16). As a group, sell-side analysts anticipate that Myovant Sciences Ltd will post -3.29 EPS for the current year.

A number of analysts have recently commented on the stock. Citigroup assumed coverage on shares of Myovant Sciences in a report on Sunday, February 2nd. They set a “neutral” rating and a $15.00 target price on the stock. Goldman Sachs Group restated a “buy” rating and set a $20.00 target price (up previously from $18.00) on shares of Myovant Sciences in a report on Tuesday, November 19th. Cowen restated a “buy” rating on shares of Myovant Sciences in a report on Monday, February 10th. Zacks Investment Research upgraded shares of Myovant Sciences from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Finally, JMP Securities restated a “buy” rating and set a $34.00 target price on shares of Myovant Sciences in a report on Tuesday, November 19th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Myovant Sciences has a consensus rating of “Buy” and an average target price of $21.54.

In other news, insider Kim Sablich sold 4,840 shares of Myovant Sciences stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $14.04, for a total value of $67,953.60. Following the completion of the transaction, the insider now owns 59,690 shares of the company’s stock, valued at approximately $838,047.60. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Frank Karbe sold 19,701 shares of Myovant Sciences stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $15.55, for a total value of $306,350.55. Following the completion of the transaction, the insider now directly owns 43,324 shares of the company’s stock, valued at approximately $673,688.20. The disclosure for this sale can be found here. In the last ninety days, insiders bought 4,046,099 shares of company stock valued at $61,228,506 and sold 46,144 shares valued at $711,963. 3.68% of the stock is owned by insiders.

Myovant Sciences Profile

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Further Reading: Cash Flow

Institutional Ownership by Quarter for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Cetera Advisors LLC Has $483,000 Stake in Office Properties Income Trust
Cetera Advisors LLC Has $483,000 Stake in Office Properties Income Trust
Cetera Advisors LLC Trims Holdings in Intercontinental Exchange Inc
Cetera Advisors LLC Trims Holdings in Intercontinental Exchange Inc
Unilever NV  Shares Bought by Cetera Advisors LLC
Unilever NV Shares Bought by Cetera Advisors LLC
Allstate Corp  Shares Acquired by Cetera Advisors LLC
Allstate Corp Shares Acquired by Cetera Advisors LLC
14,315 Shares in Johnson & Johnson  Bought by Hummer Financial Advisory Services Inc
14,315 Shares in Johnson & Johnson Bought by Hummer Financial Advisory Services Inc
Cetera Advisors LLC Has $502,000 Holdings in Gilead Sciences, Inc.
Cetera Advisors LLC Has $502,000 Holdings in Gilead Sciences, Inc.


© 2006-2020 Ticker Report